Skip to main content
MarketStoryBook

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. in 1 story

The narratives 6990.HK currently appears in, with its side and exposure in each.

Bull side

1 story
  • China Becomes Pharma's Global R&D Engine

    6990.HK in “China Becomes Pharma's Global R&D Engine”

    FadingExposure: not rated yet

    Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.

    Its antibody-drug conjugate portfolio makes it a key supplier of sought-after oncology assets to multinational pharma.

Bear side

0 stories

No bear-side stories for 6990.HK yet.